Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies

  title={Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies},
  author={Stefan {\"U}ckert and Andreas Bannowsky and Knut Albrecht and Markus Antonius Kuczyk},
  journal={Expert Opinion on Investigational Drugs},
  pages={1477 - 1483}
Introduction: Over the last 20 years, basic and clinical research activities studying the male and female sexual responses have led to several pharmacological options to treat male erectile dysfunction (ED) and female arousal and orgasmic disorders. While some strategies exclusively focus on peripheral mechanisms – such as nitric oxide/cyclic GMP signaling, which is known to play a role in the control of genital vascular and nonvascular smooth muscle – others have considered the central… 
Advances in pharmacotherapy for treating female sexual dysfunction
The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model and discusses the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.
Female Sexual Function
Endocrinologic Control of Men's Sexual Desire and Arousal/Erection.
Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.
Developments and new vistas in the field of melanocortins
The established extrahormonal effects of melanocortins on sexual activity, feeding, inflammation, tissue hypoperfusion, and traumatic damage of central and peripheral nervous system are reviewed at the light of recent findings.
Development of novel frog‐skin peptide scaffolds with selectivity towards melanocortin receptor subtypes
Naturally occurring peptides derived from frog skin secretions for selectivity and activity toward melanocortin receptors are investigated and suggest that these frog‐skin peptides could be modified for developing melancortin‐specific ligands and potentially future therapeutics.
Pharmaceutical and Energy-Based Management of Sexual Problems in Women.
The Bio-Psycho-Social Dimension in Women's Sexual Desire: 'Argumentum ad novitatem'.
An outline on know-how of introduction for sex therapy where the role of partner is narrated is suggested and the use of pharmacological agent as an adjunct scope of therapy, i.e. phosphodiasterase-5 (PDE-5) inhibitors and hormonal treatment in helping the patient with low sexual desire is highlighted.
Sex and Pharmacological Sexual Enhancement
There is a growing body of literature describing pharmacological interventions, but in many cases their utility is hard to establish due to placebo responses, side effect profiles, and negative impact of comorbidities.


Melanocortins in the treatment of male and female sexual dysfunction.
Investigations of melanocortin agonists for the treatment of sexual dysfunction are discussed with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanoc Cortinergic modulation of sexual function.
Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.
It is reported that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat, and may be the first identified pharmacological agent with the capability to treat female sexual desire disorders.
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
It is concluded that Melanotan II is a potent initiator of penile erection in men with erectile dysfunction and warrant further investigation of melanocortin agonists and antagonists onPenile erection.
A role for the melanocortin 4 receptor in sexual function
It is shown that the melanocortin 4 receptor, implicated in the control of food intake and energy expenditure, also modulates erectile function and sexual behavior, and evidence is provided that MC4R-mediated proerectile responses may be activated through neuronal circuitry in spinal cord erectile centers and somatosensory afferent nerve terminals of the penis.
Melanocortin receptors, melanotropic peptides and penile erection.
Novel data from the laboratories suggests that antagonism of forebrain MC3R may enhance melanocortin-induced erections, and melanoc Cortin agents may interact with better-studied systems such as oxytocinergic pathways at the hypothalamic, brainstem or spinal level.
An overview of pharmacotherapy in premature ejaculation.
  • H. Porst
  • Medicine, Psychology
    The journal of sexual medicine
  • 2011
An overview of the different treatment options for premature ejaculation both for lifelong (primary, "congenital") and acquired (secondary) PE is provided.
An update on the pharmacological management of female sexual dysfunction
Current pharmacological options for the treatment of FSD, particularly estrogens and androgens, which have been extensively studied are focused on, including the centrally acting agents such as flibanserin and bupropion and intravaginal DHEA and testosterone.
Discovery that a melanocortin regulates sexual functions in male and female humans
Clinical biologic pathophysiologies of women's sexual dysfunction.
This chapter encompasses data presented at the 2nd International Consultation on Sexual Medicine in Paris, France, June 28-July 1, 2003, and details the available literature concerning hormonal, neurologic, and vascular organic pathophysiologies of women's sexual dysfunctions.